Aberdeen Group
ZBIO

Aberdeen Group’s Zenas BioPharma ZBIO Stock Holding History

Aberdeen Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-75,100
Closed -$1.27M – 946
2024
Q3 		$1.27M Buy
+75,100
New +$1.35M ﹤0.01% 795

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Aberdeen Group's ZBIO Position: Q4 2024 in Review

Aberdeen Group sold out of Zenas BioPharma (ZBIO) in Q4 2024, closing a stake of 75,100 shares — an estimated $1.27M sold.

Aberdeen Group first reported a position in ZBIO in Q3 2024 and held it in 1 quarter. The position peaked at $1.27M in Q3 2024. 65 funds tracked by Wall St. Rank hold ZBIO as of Q4 2024.

  • Aberdeen Group reported no remaining Zenas BioPharma position as of Q4 2024 after selling out during the quarter.
  • Aberdeen Group sold 75,100 Zenas BioPharma shares in Q4 2024, an estimated $1.27M.
  • Aberdeen Group first reported a position in Zenas BioPharma in Q3 2024 and held it in 1 quarter.
  • Aberdeen Group's Zenas BioPharma position peaked at $1.27M in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2024.

Based on Aberdeen Group's 13F filing for Q4 2024, filed 24 Jan 2025.